crispr
therapeutics
congratulates
emmanuelle
charpentier
receiving
nobel
prize
chemistry
zug
switzerland
cambridge
globe
newswire
crispr
therapeutics
nasdaq
crsp
today
announced
professor
emmanuelle
charpentier
crispr
therapeutics
awarded
nobel
prize
chemistry
groundbreaking
work
crispr
system
professor
charpentier
crispr
therapeutics
together
rodger
novak
shaun
foy
founding
scientific
managing
director
max
planck
unit
science
pathogens
honorary
professor
humboldt
university
berlin
germany
prize
also
awarded
jennifer
doudna
professor
molecular
cell
biology
professor
chemistry
university
california
berkeley
investigator
howard
hughes
medical
institute
entire
crispr
therapeutics
team
would
like
extend
heartfelt
congratulations
professor
emmanuelle
charpentier
becoming
nobel
laureate
said
samarth
kulkarni
chief
executive
officer
crispr
therapeutics
professor
charpentier
fundamental
contribution
discovery
crispr
laid
foundation
work
crispr
therapeutics
focused
developing
transformative
medicines
potential
cure
serious
human
diseases
incredibly
proud
applaud
prestigious
recognition
received
pioneering
receiving
prestigious
nobel
prize
highest
distinction
science
extraordinary
honor
grateful
truly
moved
receive
recognition
work
crispr
system
said
professor
emmanuelle
charpentier
thoughts
go
former
lab
members
contributed
significantly
deciphering
crispr
mechanism
bacteria
award
obviously
underscores
importance
relevance
fundamental
research
field
microbiology
truly
amazed
speed
crispr
research
applications
many
diverse
areas
life
sciences
developed
recent
years
explained
emmanuelle
charpentier
sincere
acknowledgments
rodger
novak
samarth
kulkarni
executive
team
scientists
members
crispr
therapeutics
efforts
commitment
develop
crispr
technology
medicines
treat
serious
human
announcement
royal
swedish
academy
sciences
professor
claes
gustafsson
chair
nobel
committee
chemistry
commented
professor
charpentier
professor
doudna
groundbreaking
work
enormous
power
genetic
tool
affects
us
revolutionized
basic
science
also
resulted
innovative
crops
lead
groundbreaking
new
medical
added
enormous
power
technology
means
need
use
great
care
equally
clear
technology
method
provide
humankind
great
emmanuelle
charpentier
emmanuelle
charpentier
considered
expert
regulatory
mechanisms
underlying
processes
infection
immunity
bacterial
pathogens
founding
scientific
managing
director
max
planck
unit
science
pathogens
honorary
professor
humboldt
university
berlin
germany
crispr
therapeutics
together
rodger
novak
shaun
foy
prior
current
appointments
emmanuelle
charpentier
associate
professor
laboratory
molecular
infection
medicine
sweden
mims
within
nordic
embl
partnership
molecular
medicine
visiting
professor
umeå
centre
microbial
research
ucmr
umeå
university
sweden
habilitated
medical
microbiology
also
alexander
von
humboldt
professor
head
department
helmholtz
centre
infection
research
braunschweig
professor
hannover
medical
school
germany
emmanuelle
charpentier
studied
biochemistry
genetics
microbiology
university
pierre
sorbonne
university
paris
received
microbiology
research
performed
pasteur
institute
following
studies
france
spent
five
years
working
held
research
associate
positions
new
york
rockefeller
university
new
york
university
langone
medical
center
skirball
institute
biomolecular
medicine
memphis
tn
jude
children
research
hospital
moved
back
europe
lead
first
independent
research
group
guest
assistant
associate
professor
max
perutz
laboratories
max
perutz
labs
university
vienna
austria
habilitated
microbiology
crispr
therapeutics
crispr
therapeutics
leading
gene
editing
company
focused
developing
transformative
medicines
serious
diseases
using
proprietary
crispr
platform
crispr
revolutionary
gene
editing
technology
allows
precise
directed
changes
genomic
dna
crispr
therapeutics
established
portfolio
therapeutic
programs
across
broad
range
disease
areas
including
hemoglobinopathies
oncology
regenerative
medicine
rare
diseases
accelerate
expand
efforts
crispr
therapeutics
established
strategic
collaborations
leading
companies
including
bayer
vertex
pharmaceuticals
viacyte
crispr
therapeutics
ag
headquartered
zug
switzerland
subsidiary
crispr
therapeutics
r
operations
based
cambridge
massachusetts
business
offices
san
francisco
california
london
united
kingdom
information
please
visit
crispr
statement
press
release
may
contain
number
statements
within
meaning
private
securities
litigation
reform
act
amended
including
statements
regarding
crispr
therapeutics
expectations
therapeutic
value
development
commercial
potential
crispr
gene
editing
technologies
therapies
without
limiting
foregoing
words
believes
anticipates
plans
expects
similar
expressions
intended
identify
statements
cautioned
statements
inherently
uncertain
although
crispr
therapeutics
believes
statements
based
reasonable
assumptions
within
bounds
knowledge
business
operations
statements
neither
promises
guarantees
necessarily
subject
high
degree
uncertainty
risk
actual
performance
results
may
differ
materially
projected
suggested
statements
due
various
risks
uncertainties
risks
uncertainties
include
among
others
outcomes
crispr
therapeutics
planned
clinical
trials
studies
may
favorable
one
crispr
therapeutics
internal
external
product
candidate
programs
proceed
planned
technical
scientific
commercial
reasons
risks
uncertainties
described
heading
risk
factors
crispr
therapeutics
recent
annual
report
form
quarterly
report
form
subsequent
filings
made
crispr
therapeutics
securities
exchange
commission
available
sec
website
existing
prospective
investors
cautioned
place
undue
reliance
statements
speak
date
made
crispr
therapeutics
disclaims
obligation
undertaking
update
revise
statements
contained
press
release
extent
required
law
crispr
word
mark
design
logo
registered
trademarks
crispr
therapeutics
ag
trademarks
registered
trademarks
property
respective
owners
crispr
investor
contact
susan
kim
crispr
media
contact
rachel
eides
wcg
behalf
crispr
reides
